Fig. 2.

Correlation of AnxA2 expression with mAb150 cytotoxicity and epigenetic potentiation. A. Normalized IC50 values (nIC₅₀) of mAb150 in cell lines; B. Correlation between reduction in AnxA2 expression and xenograft regression following mAb150 treatment segregates two clusters, Group a: low AnxA2 expression-low efficacy, Group b: high AnxA2 expression-high efficacy; C, D. Epigenetic potentiation for mAb treatment in terms of enhanced AnxA2 expression after individual and combined treatment with epigenetic drugs 5-Aza-dC or HMTase inhibitor (5 mM and 7 mmol respectively) in A4 (C, d-i) and OVCAR3 (C, d-ii) cells; *P<0.05; **P<0.01; ***P<0.001.